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ABSTRACT
The conserved pre-mRNA splicing factor SF1 is
implicated in 30 splice site recognition by binding
directly to the intron branch site. However,
because SF1 is not essential for constitutive
splicing, its role in pre-mRNA processing has
remained mysterious. Here, we used crosslinking
and immunoprecipitation (CLIP) to analyze short
RNAs directly bound by human SF1 in vivo. SF1
bound mainly pre-mRNAs, with 77% of target sites
in introns. Binding to target RNAs in vitro was de-
pendent on the newly defined SF1 binding motif
ACUNAC, strongly resembling human branch sites.
Surprisingly, the majority of SF1 binding sites did
not map to the expected position near 30 splice
sites. Instead, target sites were distributed through-
out introns, and a smaller but significant fraction
occurred in exons within coding and untranslated
regions. These data suggest a more complex role
for SF1 in splicing regulation. Indeed, SF1 silencing
affected alternative splicing of endogenous tran-
scripts, establishing a previously unexpected role
for SF1 and branch site-like sequences in splice
site selection.
INTRODUCTION
Pre-mRNA splicing is critical for the expression of genetic
information in most eukaryotes, and alternative splicing
events largely contribute to proteome diversity in
metazoans (1,2). On average, human pre-mRNAs
contain eight exons separated by introns that vary in
length between <100 and >100000nt (3), but signals
that mark 50 and 30 splice sites are short and degenerate
(4). Precise juxtaposition of cognate exons for intron
removal is accomplished by dynamic interactions
between the pre-mRNA, ﬁve small nuclear
ribonucleoprotein particles (snRNPs) and more than 100
non-snRNP proteins (1). With few exceptions, splice sites
are deﬁned at the onset of spliceosome assembly. At this
time U1 snRNP binds the 50 splice site and the 30 splice site
is recognized by three proteins: splicing factor 1 (SF1, or
mammalian branch point binding protein, mBBP) and the
two subunits of the U2 snRNP auxiliary factor, U2AF65
and U2AF35. SF1 speciﬁcally binds the intron branch
point sequence (BPS; 5,6), which is degenerate in
mammals (YNCURAY; N=any nt, R=A or G,
Y=C or U) but almost invariant in yeast (UACUAAC;
4). The underlined adenosine acts as the nucleophile in the
ﬁrst catalytic step of splicing (1). U2AF65 interacts with
the polypyrimidine (Py) tract, located downstream of the
BPS (7). U2AF35 recognizes the conserved AG dinucleo-
tide that marks the intron 30-end (8). SF1 and U2AF65
interact in vitro and in vivo and cooperatively bind the
pre-mRNA (9–12). Recruitment of the U2 snRNP,
which involves base pairing of the U2 snRNA with the
BPS and binding of U2 snRNP proteins at and adjacent to
the BPS, displaces SF1 from the spliceosome (13).
A hnRNP K homology/Quaking 2 (KH/QUA2)
domain in the N-terminal half of SF1 (Figure 3A)
contacts the bases of the BPS and buries the
BPS-adenosine in a hydrophobic pocket of the KH-fold,
which is thought to facilitate the formation of the BPS-U2
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two central RNA recognition motifs (RRMs; Figure 3A;
14,15) and an arginine–serine-rich N-terminal region
contacts the BPS in a sequence-independent manner
(16,17). A third, non-canonical RRM of U2AF65 (or
U2AF homology motif, UHM) interacts with the N
terminus of SF1 (9–11). UHMs are also found in other
proteins, which engage in networks with ligand proteins
and coordinate constitutive and alternative splicing
(18–20).
These results implied an important role for SF1 in early
spliceosome assembly, emphasized by a requirement
of SF1 for embryonic development in mice and
Caenorhabditis elegans and viability in human cells and
yeast (10,21–24). However, depletion of SF1 from yeast
or human splicing extracts slowed the kinetics of early
splicing complex formation without compromising
splicing outcome, suggesting a kinetic role for SF1 in
splicing (13,25). Moreover, splicing defects were not
apparent after SF1 silencing (24), suggesting SF1 is only
required for the splicing of a subset of pre-mRNAs in
human cells, as reported for yeast SF1 (26), or plays
another essential role in mammalian cells. SF1 has been
implicated in changes in alternative splicing mediated by
the b-catenin/TCF4 complex involved in colorectal car-
cinogenesis, but it is not clear whether this function is
direct (27). In addition, an increased susceptibility of
Sf1
(+/–) mice to colon cancer may relate to a function in
alternative splicing (23). Finally, a mutation in SF1 in
ﬁssion yeast leads to exon skipping (28). Other ﬁndings
suggested roles for SF1 in nuclear pre-mRNA retention in
yeast (16,29) and as a repressor of transcription activation
and elongation in human cells (30,31).
To clarify the role of SF1 in splicing or other aspects of
RNA biogenesis we exploited its RNA-binding activity to
isolate cognate RNA targets from HeLa cells. We used the
crosslinking and immunoprecipitation (CLIP) method,
which combines UV crosslinking in live cells with
immunoprecipitation of short RNA fragments bound to
a protein of interest (32,33). Consistent with a function for
SF1 in mRNA maturation, the majority of SF1 target
sequences map to protein-coding genes. Of these, 77%
are found in introns and the remaining exonic targets
are preferentially located in 30 terminal exons. We
validated selected RNAs as SF1 substrates and conﬁrmed
the function of SF1 in splicing of these targets. Our results
demonstrate that SF1 is not a constitutive splicing factor,
but drives alternative splice site choices.
MATERIALS AND METHODS
Crosslinking and immunoprecipitation
CLIP was performed as described by Ule et al. (32) with
the following modiﬁcations. HeLa cells were grown in
Dulbecco’s Modiﬁed Eagle Medium (DMEM;
Invitrogen) containing 10% fetal calf serum
(Sigma-Aldrich). Cells (4 10
7) were rinsed in PBS and
irradiated at 400mJ/cm
2 in a Model 2400 Stratalinker
UV Crosslinker (Stratagene) in 10ml ice-cold Hank’s
balanced salt solution. Digestion with RNase T1
(Roche) was performed at a ﬁnal concentration of
15U/ml. SF1 and crosslinked RNA were precipitated by
incubation of the cell lysate for 1h at 4 C with mAb24D1
(directed against a region common to all SF1 isoforms; Z.
Raﬁ and A.K., unpublished data) bound to Dynabeads
Protein A (Dynal Biotech). Linker RL5 (Supplementary
Table S5) was ligated to RNA and adducts were puriﬁed
from a denaturing 10% polyacrylamide gel followed by
ligation of linker RL3. RT–PCR was performed with
primers DP5 and DP3. DNA primers for the
concatamerization step were DP5EcoR1, DP3EcoR1
and DP3. Concatamers were cloned into pCR2.1-TOPO
(Invitrogen) and sequenced by Sanger sequencing.
Tag annotation
CLIP tag sequences were mapped to the human genome
assembly version that was available for BLAST-like align-
ment tool (BLAT) searches on the UCSC genome browser
(http://genome.ucsc.edu/cgi-bin/hgBlat), hg18, and to the
ENSEMBL genome and transcript databases (34).
Determination of a weight matrix describing the
sequence preferences of SF1
To determine the sequence preference of SF1, we used a
formalism that has been initially developed in statistical
mechanics. Brieﬂy, it can be shown that if a system can
take on a certain set of states, each of them associated with
an energy, then at equilibrium, each of the states will be
visited in proportion to e  E, where E is the energy of a
state, and   is the inverse temperature. In our case, the
states correspond to all the ways one or more proteins can
be bound to the RNA. In the simplest example there is
only a single type of protein and a short RNA fragment
that can be bound in one way only. Let S be the
concentration of the RNA, P the concentration of the
protein and C the concentration of the complex. RNA–
protein binding can be described by S+P,
kf
kr
C with kf and
kr being the forward and reverse rate constants. Let B and
U be the measured intensities of bound and unbound
RNA, with a scaling factor  0 relating the signal intensity
to the RNA concentration and PT be the total
protein. Finally, let us assume that we can write the dis-
sociation rate of the protein from an RNA as
K ¼ð kr =kfÞ¼k0 expð EðsÞÞ, where E(s) is the sequence-
dependent energy of binding between the RNA and the
protein. After rewriting the rate equations in terms of
these quantities, we derive the following relationship:
1
U ¼ exp½EðsÞ =k0 PT =B   b0
  
, which relates the intensity
of unbound RNA to the total protein concentration and
the intensity of bound RNA. With the assumption that the
energy of interaction between the RNA and protein is
composed of the individual energy contributions of indi-
vidual positions in the binding site, and that these contri-
butions depend only on the nucleotide that is present at
that position in the binding site, the proportionality factor
is exp EðsÞ ½  =k0 depends only on the sequence of the RNA.
That is, assuming a weight matrix model, EðsÞ can be
written as EðsÞ¼
PL
i¼1 EðsiÞ, where L is the length of
the binding site (and the number of columns in the
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site. The probability to observe nt si at position i of the
binding site is proportional to e EðsiÞ as mentioned above.
Because we have three measurements for each individual
RNA sequence, corresponding to three different total
protein concentrations, we can ﬁt a straight line to the
three data points and the slope of this line corresponds
to exp EðsÞ ½  =k0. Furthermore, because EðsÞ can be
decomposed into the binding energies of individual pos-
itions in the binding site, the relative binding energies of
the mutational variants of a given position in the binding
site only differ in the relative contribution of their respect-
ive nucleotides at that position. That is, the entry wB
i in the
weight matrix, which represents the expected frequency of
nucleotide B at position i in a binding site of the protein is
given by
exp EðBÞ ½ 
P
B02fA;C;G;Ug
exp½EðB0Þ 
¼
exp
P
j6¼i
EðsjÞþEðBÞ
"#
P
B02fA;C;G;Ug
exp
P
j6¼i
EðsjÞþEðB0Þ
"# ;
which can be derived from the slopes ﬁtted above.
Determination of sequence motifs overrepresented in SF1
CLIP tags
We compared the frequency of tetrameric motifs in
isolated SF1 CLIP tags to randomized sequences with
the same nucleotide composition, which were obtained
by shufﬂing the tags. Motifs, whose frequency in the real
and the randomized sets were signiﬁcantly different, were
identiﬁed as follows. Given the frequencies of the motifs
and the total number of tetramers in the real and
randomized sets, we computed the posterior probability
for the model that assumes that the frequency of a motif
is different as opposed to being the same between the two
datasets, as described (35). Motifs that were found
enriched in introns and exons are shown in
Supplementary Table S3. We also compared the frequency
of tetrameric motifs in exonic/intronic tags with those
found genome-wide in exons or introns as follows. We
downloaded mRNAs sequences to Genbank (www.nlm.
nih.gov) and, based on the Entrez Gene database, we
chose the longest mRNA corresponding to each annotated
gene in the genome. We mapped the mRNAs to the hg18
release of the human genome assembly, which we obtained
from the University of California at Santa Cruz (gen-
ome.cse.ucsc.edu) with the GMAP alignment program
(36). This mapping deﬁned exonic and intronic genomic
regions. We then sampled for each data set (exonic or
intronic tags) 100 randomized data sets. Each of these
datasets was generated by choosing with uniform prob-
ability the same number and length of regions as present
in the CLIP sets from the appropriate type of region in the
genome. For each of the 100 randomized sets, we
computed the frequency of all possible tetramers.
Supplementary Table S4 shows the frequency of the tetra-
mers in the CLIP sets and the z-value of this frequency
with respect to the frequencies computed in the
randomized datasets.
In vitro transcription and RNA puriﬁcation
RNAs were synthesized in the presence of [a-
32P]UTP
with the T7-MEGAshortscript kit (Ambion) and
gel-puriﬁed. Additional G’s were added to the 50-end of
the RNAs to optimize transcription efﬁciency. The BPS
RNAs (GGGGAGUAUACUAACAAGUUGAAUU;
the BPS is underlined) are based on RNAs used by
Berglund et al. (5), but contained four 50 terminal G’s
instead of a C.
Protein expression and puriﬁcation
The SF1 KH/QUA2 domain was expressed and puriﬁed
as described (6). His6-SF1-C4 and His6-SF1-C4/W22A
(10,11) were puriﬁed on Ni-NTA columns (Qiagen)
under native conditions. GST-U2AF651-94 (16) was
puriﬁed on glutathione-agarose (Sigma). Puriﬁed
proteins were dialyzed against 20mM HEPES-KOH pH
7.9, 100mM KCl, 20% glycerol, 0.2mM EDTA and
0.5mM dithiothreitol.
Electrophoretic mobility shift assays
SF1-KH/QUA2 was incubated for 15min at room tem-
perature in 10-ml reactions in the presence of
[a-
32P]UTP-RNA ( 1pmol for Figure 2A,  50pmol for
Figures 3C and 4B), 16mM Tris–HCl pH 8.0, 80mM
NaCl, 4mM imidazole, 2mM b-mercaptoethanol, 5mg
tRNA and 7U rRNasin (Promega). Reaction products
were resolved in native 8% polyacrylamide gels (acryl-
amide:bisacryamide = 80:1) in 1 TBE at 4 C for 3h at
100V.
Cooperative binding was performed for 15min at room
temperature in 10-ml reactions containing
GST-U2AF651-94 and His6-SF1-C4 or His6-SF1-C4/
W22A, 50pmol [a-
32P]UTP-RNA, 80mM KCl, 16mM
Hepes-KOH pH 7.9, 16% glycerol, 2.4mM MgCl2,
0.4mM DTT, 0.16mM EDTA, 2.5mg tRNA and 4U
rRNasin. Reaction products were resolved in native 5%
polyacrylamide gels in 1 TBE at 4 C for 3h at 150V.
Autoradiographs were quantiﬁed with the Molecular
Imager FX (BioRad) and software Quantity One V 4.2.1
(BioRad).
RNA interference and semiquantitative RT-PCR of
pre-mRNA targets of SF1
HeLa cells were grown in DMEM/high glucose containing
10% fetal calf serum (Sigma-Aldrich). Cells (2 10
5) were
transfected in the presence of 73nM SF1 or SF3a120
siRNAs (Dharmacon; Supplementary Table S5) and
oligofectamine (Invitrogen) according to Dharmacon’s in-
structions. Control transfections were performed in the
presence of siRNA LUC, targeting ﬁreﬂy luciferase
(LUC; 37) or in the absence of siRNAs. Duplicate
samples were lyzed 48h post-transfection for western
blot analysis (24) and isolation of cytoplasmic RNA
with the RNeasy Mini kit (Qiagen). RNA was treated
with 2U RQ-DNase (Promega) for 45min at 37 C and
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40 C in the presence of 4mg cytoplasmic RNA, 4mg
oligo dT(12–18) (Sigma-Aldrich), 40U rRNasin and 200U
MMLV-RT (Invitrogen). PCR was performed with the
Expand High-Fidelity PCR system (Roche) for 28
cycles. Control PCR reactions of 32 cycles indicated amp-
liﬁcation in the linear range (not shown). Primers for amp-
liﬁcation of SF1, SF3a120, H3F1 mRNAs have been
described elsewhere (24). Other primers are listed in
Supplementary Table S5. Forward primers were
50-end-labeled with [g-
32P]-ATP and T4 polynucleotide-
kinase (Invitrogen). PCR products were separated in
native 4% polyacrylamide gels, visualized by autoradiog-
raphy and quantiﬁed by phosphoimaging as above.
Alternatively, PCR products were separated in agarose
gels and quantiﬁed with ImageJ 1.410 (National
Institutes of Health). PCR products were gel-puriﬁed
and sequenced.
RESULTS
Isolation of in situ RNA targets of SF1 from HeLa cells
We isolated SF1–RNA complexes from a whole-cell lysate
of UV-irradiated HeLa cells with antibody mAb24D1 (see
‘Materials and Methods’ section). SF1 was efﬁciently
removed from the lysate after immunoprecipitation in
the presence, but not absence of mAb24D1 (Figure 1A).
Non-speciﬁc binding of RNA to beads in the absence of
antibody was not observed (I. Bagdiul and A. Kra ¨ mer,
data not shown). Following 50-end-labeling of RNA,
SF1–RNA complexes were resolved by PAGE and
transferred to nitrocellulose. Autoradiography revealed a
series of bands between 50 and 220kDa superimposed on
a smear of radioactivity (Figure 1B). SF1 isoforms
detected by mAb24D1 in HeLa cells migrate between 70
and 85kDa; SF1 crosslinked to RNA fragments of  30
nts are expected to migrate at least 10kDa higher.
Denaturing PAGE of RNA puriﬁed from consecutive
slices of a membrane comparable to that shown in
Figure 1B revealed an increase in RNA length with
increasing size of the RNA–protein complexes
(Figure 1C), suggesting that RNAs of increasing size are
crosslinked to one protein rather than RNAs of similar
size distribution being crosslinked to proteins of different
molecular mass. As RNAs (CLIP tags) of 50–200nt are
best suited for analysis (32), we further processed SF1–
RNA complexes of 80–100kDa, followed by cloning and
conventional sequencing.
Distribution of RNA targets in the human genome
We obtained  360 SF1 CLIP tags and compared their
sequences to the human genome by BLAT searches.
Sequences with <90% match to the genome, multiple
hits and exact duplicates were removed, resulting in a
ﬁnal set of 227 sequences (Supplementary Table S1). The
majority of these (193) are located in protein-coding genes
and 14 in genes of non-coding RNAs (Figure 1D). A total
of 20 CLIP tags are present in intergenic regions, 7 of
which map to the opposite strand of known genes.
Intergenic CLIP tags were also found in other studies
and may correspond to yet unannotated transcripts
(38–41).
SF1 CLIP tags in protein-coding genes are largely
conﬁned to introns (Figure 1E and Supplementary Table
S1). Despite SF10s function in BPS binding (5,6), only 19
intronic tags are present at or close to 30 splice sites, two
map to 50 splice sites and the remainder are located >40nt
from intron ends. Four intronic CLIP tags map to
snoRNAs. One of these spans the intron–snoRNA
border and is thus derived from the intron, which may
also be true in the other cases.
Among 40 exonic CLIP tags, 21 are located in coding
sequences, two in 50-untranslated regions (UTRs) and 17
in 30-UTRs (Figure 1E). Moreover, of the 43 tags located
within exonic regions of known genes, 22 originated in 30
terminal exons (Supplementary Table S1). Since human
genes have on average 8–9 exons (3), this distribution in-
dicates an enrichment of 30 terminal exons among the
exonic tags (P-value 9.9 x 10
 10 in a binomial test
assuming a probability to observe a 30 terminal exon of
1/8). Additionally, in repeated sampling of 43 human
exons from all human genes (dataset described in
Figure 1. Isolation of SF1–RNA complexes from crosslinked HeLa
cells. (A) Lysates of crosslinked HeLa cells (lane 1) were incubated
with Dynabeads in the presence (lane 2) or absence (lane 3) of
mAb24D1. Input (lane 1) and unbound material (lanes 2 and 3) were
separated by 10% SDS–PAGE. After transfer to nitrocellulose SF1 was
detected with mAb24D1. Protein size markers (in kDa) are indicated on
the left. (B) SF1–RNA complexes eluted from mAb24D1-coupled
Dynabeads were separated by 10% Bis–Tris NuPAGE and visualized
by autoradiography. Protein size markers are shown on the left. Gel
slices used for RNA analysis in panel C are marked on the right.
(C) RNA extracted from nitrocellulose slices 1–5 in panel B was
resolved in a denaturing 13% polyacrylamide gel. DNA size markers
(in bp) are shown on the left. (D) Pie chart representing the number of
SF1 CLIP tags in the protein-coding genes, genes encoding ncRNAs
and in intergenic regions. (E) Pie chart representing the number of SF1
CLIP tags in introns or exons of protein-coding genes. Exonic CLIP
tags were further divided into coding sequences (CDS), 50- and
30-UTRs and exon–exon junctions.
Nucleic Acids Research,2011, Vol.39, No. 5 1871‘Materials and Methods’ section), we only obtain an
average of four 30 terminal exons, indicating that targets
in such exons are indeed overrepresented among SF1
CLIP tags. In addition, three CLIP tags span exon–exon
junctions, suggesting that SF1 can bind mature mRNA.
Finally, 42% of the CLIP tags in protein-coding genes are
located in regions that are subject to alternative splicing
(Supplementary Table S1).
Thus, SF1 mainly targets pre-mRNAs and binding sites
are associated with constitutive and alternatively spliced
regions of transcripts. An unexpectedly high percentage of
SF1 target sites are located in 30-UTRs and SF1 appears
to bind mature mRNA as well. Compared with other
studies that combined CLIP with high-throughput
sequencing (38–41), our dataset only provides a glimpse
at possible in situ SF1 binding sites and it is not surprising
that, with a few exceptions containing two or more CLIP
tags, only one SF1 CLIP tag was found per gene.
RNA binding preferences of SF1
SF1 speciﬁcally recognizes the BPS (5,6). Yeast SF1
selected the consensus BPS from a pool of randomized
sequences (42), but information on binding preferences
of human SF1 is limited. Mutational analyses and the
NMR structure of the KH/QUA2 RNA-binding domain
of human SF1 in complex with a UACUAAC-containing
RNA showed that the URA in the 30 half of the BPS is
speciﬁcally recognized, whereas interactions with the 50
half are less important (5,6,43). About 80% of the SF1
CLIP tags contained at least one copy of the URA motif;
however, this sequence was not speciﬁcally enriched in our
dataset compared to randomized sequences with the same
overall length and nucleotide composition.
To precisely deﬁne binding preferences of human SF1,
we tested 25-nt RNAs containing the consensus BPS or
mutations at all BPS positions in electrophoretic mobility
shift assays (EMSAs) for binding to recombinant
SF1-KH/QUA2 protein (Figure 2A). The results were
used to infer a weight matrix describing the sequence spe-
ciﬁcity of SF1 (Figure 2B and Supplementary Table S2).
The derived motif resembles the human BPS consensus,
except that SF1 strongly prefers an A at position  4 for
optimal binding, whereas no nt bias is found at this
position in the BPS consensus (4). The motif also comes
close to the yeast BPS but lacks the preference for U at
position  5. The information score at individual positions
in the weight matrix is generally less than one
(Supplementary Table S2), suggesting that human SF1
can bind a large variety of sequences. This is also reﬂected
in only 4.4% of the CLIP tags containing the sequence
ACUNAC (which we will refer to as the SF1 binding
motif).
In contrast, Py-rich motifs were the most signiﬁcantly
enriched sequences in the CLIP tags relative to unrelated
sequences with the same mononucleotide frequency.
Approximately half of both intronic and exonic tags con-
tained at least one occurrence of the motifs CCUG or
UCCU (Supplementary Tables S3 and S4). CCUG
repeats, which form mismatched stems, are known
binding sites for MBNL proteins; the repeats sequester
Figure 2. Determination of the optimal SF1–RNA-binding motif.
(A) In vitro-transcribed RNAs containing the wild-type or mutant
BPS were incubated with buffer or SF1-KH/QUA2 (5, 10 and 20mM;
indicated by triangles above the ﬁgure). Reaction products were
separated by native PAGE and visualized by autoradiography. The
same wild-type images were used for positions –5/–4/–3, –2/+1 and
BP/–1. (B) Web logo representing the weight matrix for each position
of the SF1 binding site derived from the quantiﬁcation of the data
presented in A.
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myotonic dystrophy and other disorders (44). Such
repeats are not observed in the CLIP tags
(Supplementary Table S1). MBNL1 also binds a stem–
loop structure ﬂanked by two CCUG motifs and
prevents U2AF65 binding upstream of a regulated 30
splice site (45). That the CCUG motifs in the CLIP tags
function in a similar way is unlikely, since only few are
located close to splice sites. UCCU motifs (and to a lesser
extent CCUG motifs) in SF1 CLIP tags are often
embedded in longer Py-stretches, which may represent
binding sites for U2AF65 (46). Py-rich motifs, particularly
UCC, were also enriched with respect to random frag-
ments chosen from the genome-wide set of exons or
introns (Supplementary Table S4).
To further test SF1 binding preferences and validate
CLIP tags as SF1 substrates, we analyzed the interaction
of SF1 with in-vitro-transcribed RNAs representing 11
CLIP tags. SF1-KH/QUA2 bound 10 of the RNAs
tested (Figures 3C and 4B; Supplementary Figure S1;
data not shown). Mutations in potential SF1 binding
sites introduced into six RNAs abolished the interaction
(see below and data not shown). For example, SF1-KH/
QUA2 efﬁciently bound RNA 2–50, which contains three
partial matches to the SF1 binding motif and corresponds
to a CLIP tag in intron 1 of cGMP-inhibited 30,50-cyclic
phosphodiesterase 3A (PDE3A) pre-mRNA (Figure 3B
and C). Mutation of all three motifs (M1) abolished SF1
binding. SF1 bound the 50 most site (M3) with high
afﬁnity, whereas binding to the other two sites (M2 and
M4) was weak. Binding to mutant RNAs containing two
SF1 binding motifs (M5 and M6) was additive, suggesting
that more than one molecule of SF1-KH/QUA2 can
interact with RNA 2–50. This is also evident from the
difference in migration of complexes of SF1-KH/QUA2
and RNAs with one or more binding sites.
These results indicate that SF1 binds RNA recognizing
ACUNAC motifs. Variant ACUNAC motifs are bound
with different afﬁnities, suggesting that other factors, e.g.
neighboring sequences or RNA conformation, may inﬂu-
ence SF1 binding in vitro.
Cooperative interaction of SF1 and U2AF65 with RNA
targets
Association of SF1 with branch sites likely reﬂects SF1
and U2AF binding to adjacent RNA sequences; in prin-
ciple, SF1 and U2AF interactions with RNA could be
competitive, neutral or cooperative. To address this, we
performed EMSA with CLIP tag-derived RNAs and re-
combinant U2AF651-94 and SF1-C4 (Figure 3A),
comprising the domains required for binding each other
and RNA (11,16). U2AF65 and SF1-C4 alone bound
RNA 2-50 (Figure 3D, lanes 2–6 and 7), containing an
11-nt Py tract following the 50 most SF1 binding motif
(Figure 3B). A ternary complex formed in the presence
of both proteins, while the SF1-C4/RNA complex
decreased (lanes 8–12). Consistent with cooperative
RNA binding of SF1 and U2AF65, the ternary complex
formed at a lower U2AF65 concentration when SF1 was
present (compare lanes 2 and 3 with lanes 8 and 9).
Cooperativity was also observed with mutant RNAs
2-50/M2, M3 and M4, which are less efﬁcient substrates
for SF1-KH/QUA2 and SF1-C4 than 2-50/WT, and with
other CLIP tags (data not shown). Protein–RNA
complexes migrated more slowly in the presence of high
U2AF65 concentrations (Figure 3D), most likely due to
binding of more than one U2AF65 molecule (14).
The importance of the U2AF65 interaction for SF1
RNA binding was further illustrated with CLIP tag
1-10, mapping to the 30 splice site of exon 8 of the ﬁbro-
blast growth factor receptor 1 oncogene partner
(FGFR1OP) pre-mRNA. It contains a UCUCAC as the
closest match to the ACUNAC motif and a 16-nt Py tract
(Figure 4A). Neither SF1-KH/QUA2 nor SF1-C4 bound
the corresponding RNA (1–10/WT), but mutation of
UCUCAC to UCUAAC (RNA 1–10/M) converted the
RNA into an efﬁcient SF1 substrate (Figure 4B and C,
lanes 6). Thus, at least in this sequence context, a C at
position  1 is not compatible with SF1 binding, whereas a
U at position  4 is tolerated, in agreement with the mu-
tational analysis of the BPS (Figure 2). U2AF65 bound
both RNAs with similar efﬁciency (Figure 4C, lanes 2–5)
and ternary complexes in the presence of SF1-C4 formed
more readily with RNA 1–10/M (lanes 7–10). No ternary
complexes were apparent in the presence of SF1-C4/
W22A, which does not interact with U2AF65 (11) but
binds RNA 1-10/M (lanes 11–15). The more efﬁcient for-
mation of slow-migrating complexes with RNA 1–10/M
can be explained by binding of SF1-C4/W22A and
U2AF65 independently of one another. Thus, the ability
of U2AF65 to increase SF10s afﬁnity for RNA 1–10/WT
depends on the interaction between the two proteins. We
conclude that U2AF65 can recruit SF1 to RNAs with
suboptimal binding sites, explaining the isolation of
CLIP tags with suboptimal or no SF1 binding motifs
and containing Py-rich motifs.
Effects of SF1 depletion on splicing
A function of SF1 in splicing endogenous pre-mRNA
targets was tested by RT–PCR after RNAi-mediated
down-regulation of SF1 in HeLa cells. SF1 mRNA
levels were reduced to  15% of the LUC or mock
controls after transfection of two SF1 siRNAs, and SF1
protein was barely detectable (Figure 5A). Neither mRNA
nor protein levels of the U2 snRNP-associated SF3a120
were affected after SF1 knockdown, as shown previously
(24). In contrast, depletion of SF3a120 (used as a positive
control, since it is thought to be a constitutive splicing
factor) strongly reduced SF1 mRNA and protein levels.
Negative effects on the expression of the intron-less H3F1
mRNA were not observed.
When we tested the splicing of pre-mRNAs containing
CLIP tags, SF1 depletion modulated the ratio of inclu-
sion/skipping of alternative cassette exons. We observed
increased exon inclusion after SF1 silencing compared to
the controls for FGFR1OP, TNFAIP3-interacting protein
1 (TNIP1) and procollagen-lysine 1, 2-oxoglutarate
5-dioxygenase 2 (PLOD2) pre-mRNA splicing
(Figure 5B–D). The ratio of both, exon inclusion and
skipping was changed in the case of splicing of the
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(UPF3A) pre-mRNA. The mRNA containing exons 1–5
was strongly reduced compared to the controls, whereas
levels of mRNAs lacking exon 4 or exon 4 plus exon 2 or 3
(both of which are 107nt in length) increased (Figure 5E).
When we analyzed RT–PCR products from an
independent experiment with SYBR Green, the 318bp
product from control cells was resolved into two closely
migrating bands (Supplementary Figure S2B). PCR with
primers in exons 2 or 3 and 5, as well as sequencing
revealed that the slower migrating band corresponded to
exons 1, 3 and 5, whereas the faster migrating band
Figure 3. Cooperative binding of SF1 and U2AF65 to an endogenous SF1 target. (A) Scheme of SF1 and U2AF65 constructs used for EMSA. The
U2AF65 interaction domain (U2AF65-ID), KH/QUA2 domain and the zinc knuckle (Zn) of SF1 are shown, as well as the arginine/serine-rich (RS)
domain, RRMs 1 and 2 and the UHM of U2AF65. The star above the U2AF65-ID of SF1-C4 indicates the location of the W22A mutation.
Numbers indicate amino acids of the truncated proteins. Variability in the length of SF1 isoforms is indicated by dashed lines. (B) RNAs corres-
ponding to CLIP tag 2-50 (wild-type, WT, or mutants M1–M6) were transcribed in vitro. SF1 binding motifs are indicated in bold. Mutations are
underlined. (C) Wild-type and mutant RNAs were incubated with buffer or SF1-KH/QUA2 (5, 10 and 20mM; indicated by triangles). Reaction
products were separated by native PAGE and visualized by autoradiography. (D) RNA 2–50 WT was incubated with buffer or U2AF651–94 (0.2,
0.5, 1, 2 and 4mM; indicated by triangles) in the absence or presence of 6.6mM SF1-C4 as indicated. Reaction products were separated by native
PAGE and visualized by autoradiography. The migration of RNA 2–50 bound to U2AF651–94 (open arrowheads), SF1-C4 (vertical bar) or both
(closed arrowheads) is indicated.
1874 Nucleic Acids Research, 2011,Vol.39, No. 5contained exons 1, 2 and 5 (data not shown). SF1 silencing
reduced the exon 1-2-5 mRNA to background levels,
whereas the exon 1-3-5 mRNA was strongly increased.
Together, these results show that SF1 can act as a
negative or positive regulator of exon inclusion.
Of note, although depletion of SF3a120 resulted in a
general reduction of mRNA levels (as apparent by inspec-
tion of the autoradiographs), in some cases the ratio of
spliced products was also changed compared to controls
(Figure 5B–E). This result is not unexpected, since
SF3a120 has been shown to be involved in alternative
splicing in Drosophila (47).
PDE3A pre-mRNA was identiﬁed as a potential SF1
target by three CLIP tags (Figure 3 and Supplementary
Table S1). SF1 and SF3a120 knockdown reduced the
single endogenous PDE3A mRNA detected in HeLa
cells to 51–53 and 19%, respectively, compared to the
controls (Supplementary Figure S3A), suggesting that
SF1 affects the maturation or stability of PDE3A
mRNA. Similarly, the level of a single mRNA of the
asparagine-linked glycosylation 8 homolog (ALG8)
decreased to 50–54 and 39% after SF1 and SF3a120 de-
pletion, respectively (Supplementary Figure S3B). Thus,
SF1 knockdown negatively affects the expression of
these pre-mRNAs, although to a lesser extent than deple-
tion of SF3a120.
These data demonstrate that SF1 indeed functions in
splicing. However, it does not appear to be a constitutive
splicing factor. SF1 may be required for the splicing of all
introns of PDE3A and ALG8 pre-mRNAs. In contrast, in
other cases tested, SF1 downregulation changed the ratio
of mRNA isoforms without decreasing total mRNA
levels, as observed after depletion of SF3a120. We
conclude that SF1 plays a role in alternative splicing
events.
DISCUSSION
We have isolated RNAs bound to SF1 in HeLa cells to
clarify SF10s role in splicing and/or other steps of RNA
biogenesis. As expected for a protein that functions in
mRNA maturation, the majority of SF1 targets mapped
to protein-coding genes. We determined the RNA binding
preferences of SF1, validated selected CLIP tags as bona
ﬁde SF1 ligands and demonstrated a role for SF1 in the
splicing of several pre-mRNAs identiﬁed as potential
targets. Our data indicate that SF1 is not required for
the splicing of all introns, but inﬂuences alternative
splicing decisions.
A role for SF1 in alternative splicing
Silencing of SF1 changed the ratio of exon inclusion/
skipping in alternatively spliced products of several en-
dogenous pre-mRNAs identiﬁed as potential SF1 targets
(Figure 5 and Supplementary Figure S2). Depending on
the event analyzed, SF1 activated or repressed exon inclu-
sion, which is not without precedent. Nova, Fox and
several hnRNP proteins regulate alternative splicing in
both directions (2). Moreover, CLIP combined with
high-throughput sequencing (HTS) provided a
genome-wide view of splicing factor binding sites and
demonstrated that Nova, Fox2 and PTB regulate exon
inclusion/skipping depending on their binding sites with
respect to the regulated exon (38,39,41).
Previous, mostly indirect evidence is in line with a
function of SF1 in alternative splicing. First, exon inclu-
sion into mRNAs of the soluble histocompatibility leuko-
cyte antigen DQb correlated with the strength of SF1
binding to BPS RNAs carrying disease-associated muta-
tions (48). Second, SF1 expression is negatively regulated
by the b-catenin/TCF4 complex involved in colorectal car-
cinogenesis and SF1 is required for changes in alternative
splicing mediated by this complex (27). A direct involve-
ment of SF1 is not clear, since b-catenin is itself implicated
Figure 4. Cooperative binding of SF1 and U2AF65 to an endogenous
SF1 target with a suboptimal SF1 binding site. (A) RNAs correspond-
ing to wild-type (WT) and mutant (M) CLIP tag 1–10 were transcribed
in vitro. A SF1 binding motif is indicated in bold. The mutation is
underlined. (B) Wild-type and mutant RNAs were assayed as in
Figure 3C. (C) Wild-type and mutant RNAs were tested as in Figure
3D in the absence or presence of 6.6mM SF1-C4 or SF1-C4/W22A as
indicated. The migration of RNAs bound to U2AF651–94 (open
arrowheads), SF1-C4 (vertical bar) or both (closed arrowheads) is
indicated.
Nucleic Acids Research,2011, Vol.39, No. 5 1875in splicing (49). Third, an increased susceptibility to colon
cancer of Sf1
(+/–) mice could be caused by aberrant
splicing due to reduced SF1 levels (23). Finally, a
mutation in SF1 in ﬁssion yeast leads to exon skipping
(28) and Saccharomyces cerevisiae SF1 is required only
for the splicing of pre-mRNAs with suboptimal splice
sites (26).
SF1 silencing also reduced the levels of single endogen-
ous mRNAs (Supplementary Figure S3). Whether this is
due to defects in splicing one or more introns is not clear.
Lower mRNA levels rather than aberrantly spliced
products may be due to faulty splicing upon SF1 deple-
tion, which can introduce premature termination codons
into mRNAs and cause mRNA degradation by
nonsense-mediated decay (50).
SF1 is not an isolated case of a splicing factor thought
to merely function in constitutive splicing but involved in
alternative splice site choice. Other examples are U2AF65
and SF3a120 (47,51). It would be interesting to see
whether these and possibly other proteins are required
for all constitutive splicing events or, similar to SF1,
also participate in the splicing of a subset of introns.
The SF1–BPS interaction is thought to facilitate base
pairing of U2 snRNA with the BPS by pre-bulging the
branch point adenosine (6). If SF1 is involved in the
splicing of only certain introns, does another protein
take over SF10s role? The arginine–serine-rich domains
of U2AF65 and SR proteins contact the phosphates of
the BPS and could aid U2 snRNP in binding the BPS in
the absence of SF1 (16,17,52). Moreover, the U2
snRNP-associated p14/SF3b14a, which speciﬁcally binds
the branch point adenosine during A complex assembly
(53,54), could facilitate base pairing.
SF1 binding preferences
An advantage of CLIP over other methods to identify
targets of RNA-binding proteins is the possibility to
locate approximate binding sites within targets and
deﬁne consensus binding motifs (32,38–41,55). SF1 specif-
ically recognizes the BPS (5,6,43). However, BPS-like se-
quences were not enriched in our dataset compared to
random sequences with the same mononucleotide compos-
ition. Analysis of SF1 binding to a comprehensive set of
BPS mutants deﬁned ACUNAC as the consensus SF1
binding motif (Figure 2), which agrees in large part with
previous limited mutational studies and the human
Figure 5. Effects of RNAi-mediated depletion of SF1 on the splicing of
CLIP tag-containing pre-mRNAs. (A) cDNA from HeLa cells trans-
fected in the absence (mock) or presence of siRNAs targeting SF1 (SF1
#1 and #2), luciferase (LUC) or SF3a120, as indicated on top of each
panel, was PCR-ampliﬁed with primers speciﬁc for SF1, SF3a120 and
H3F1 mRNAs, products were separated by PAGE and visualized by
autoradiography. The numbers below the ‘mRNA’ panels indicate the
percentage of mRNA normalized to the LUC control. Data represent
the average of two experiments; the standard deviations were <1. HeLa
cell lysates prepared in parallel were separated by SDS–PAGE and
proteins revealed by western blotting. (B, C, D and E) The effect of
SF1 depletion on the splicing of endogenous FGFR1OP (B), TNIP1
(C), PLOD2 (D) and UPF3A (E) pre-mRNAs was analyzed as in panel
A. Sizes of DNA markers and spliced products are shown to the left
and right of the images, respectively. Results of at least two experi-
ments were quantiﬁed and are expressed as percent exon inclusion
below the panels in addition to the standard deviation (std. dev.).
The asterisk (panel B) indicates a PCR product that could not be
identiﬁed by sequencing. The schemes depict pre-mRNA regions
subject to alternative splicing (not to scale) and observed splicing
patterns. Forward (F) and reverse (R) PCR primers including the
exon number (E#) are shown above the schemes. Filled circles
indicate the approximate location of CLIP tags. TNIP exon 2 is
transcribed from an alternative promoter and not included in
mRNAs transcribed from exon 1.
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sequence identiﬁed downstream of exons speciﬁcally
included in muscle (56). An exception is position  4,
where SF1 favors an A, but no preference is evident in
the consensus BPS (4), nor is the A speciﬁcally recognized
in the SF1–BPS solution structure (6). In addition, a  4A
to G mutation did not affect SF1 function in previous
studies (5,43). Another exception is position  1, where
our data reveal the lowest information score for SF1
binding, although a  1 C can compromise SF1 binding
(Figures 2 and 4, Supplementary Table S2). The SF1–BPS
solution structure indicated coordination of a purine at
this position (6); however, a  1 A to G mutation of an
in vivo splicing reporter reduced SF1 function (43).
An information score of <1 at individual positions of
the weight matrix (Supplementary Table S2) and <5% of
the SF1 CLIP tags containing an exact match to the
ACUNAC motif suggest a more relaxed RNA binding
speciﬁcity of human SF1 compared to other splicing
factors, which mirrors the variability of the mammalian
BPS (4). This agrees with an RNA binding afﬁnity of SF1,
even for the consensus BPS, in the micro-molar range
(5,6). In addition, the efﬁciency of SF1 binding to CLIP
tag-derived RNAs did not always correlate with a perfect
or suboptimal ﬁt to the SF1 binding motif, suggesting that
other parameters, such as neighboring sequences or RNA
secondary structure, may inﬂuence the interaction. This
may explain the variability in SF1 binding preferences
observed in different experimental systems (see above).
The enrichment of Py-rich motifs in SF1 CLIP tags,
many of which resemble U2AF65 binding sites (46;
Supplementary Tables S1 and S3), is not unexpected,
since SF1 binds RNA cooperatively with U2AF65
(9,43). Importantly, we not only observed cooperativity
when SF1 alone bound RNA, but also when SF1–RNA
binding was not evident (Figures 3D and 4C; data not
shown). Thus, the interaction with U2AF65 increases
the binding repertoire of SF1. Domains similar to the
U2AF65 UHM, which contacts SF1, are present in
other splicing factors engaging in networks with UHM
ligands, including SF1 (19,20; G. Gregorovic and A.
Kra ¨ mer, unpublished data). We therefore speculate that
not only U2AF65, but also other UHM proteins direct
SF1 to appropriate binding sites in a pre-mRNA and
regulate its function in the selection of speciﬁc splice sites.
Potential additional functions of SF1
Yeast SF1 dissociates from the spliceosome upon U2
snRNP recruitment (13) and human SF1 is most likely
displaced from the BPS by binding of SF3b14a and base
paring of the U2 snRNA (53,54,57), consistent with the
absence of SF1 from late spliceosomes or spliced mRNPs
(1,58). Thus, it may be surprising that 30 terminal exons
were overrepresented among the SF1 CLIP tags and that
SF1 bound RNA spanning exon junctions. The binding of
SF1 to 30 terminal exons could hint to a role in coupling
splicing of the last intron to 30-end processing, as observed
for U2AF65 and the U2 snRNP (59–61). Interestingly, the
alternative splicing factor Nova also binds 30 UTRs and
regulates alternative polyadenylation in the brain (38).
Similar to other splicing factors SF1 shuttles between
the nucleus and the cytoplasm (G. Moreau and A.
Kra ¨ mer, unpublished data) and may thus have an add-
itional role in the cytoplasm. For example, shuttling SR
proteins function in constitutive and alternative splicing,
mRNA export and translation, U2AF65 and PTB associ-
ate with deﬁned sets of mRNAs in the cytoplasm, and
TIA-1 plays a role in alternative splicing and translation
repression (62–65).
In conclusion, our data conﬁrm a function of SF1 in
splicing, possibly of a subset of introns, and demonstrate a
role in alternative splicing events. Future studies
combining CLIP with HTS should yield information re-
garding SF1 binding with respect to regulated exons,
which will help elucidate the mechanism of SF1 action.
The resemblance of the SF1 binding motif to the mamma-
lian consensus BPS moreover suggests that the SF1–BPS
interaction plays an important role in alternative splicing
decisions. Furthermore, the identiﬁcation of an unexpect-
edly high number of SF1 target sites in 30 terminal exons
hints to additional functions of SF1 in other steps of
mRNA biogenesis.
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